Halozyme Therapeutics, Inc. (HALO)
70.68
-0.85
(-1.19%)
USD |
NASDAQ |
Jun 08, 16:00
70.68
0.00 (0.00%)
After-Hours: 19:29
Halozyme Therapeutics Shareholders Equity (Quarterly) : 219.64M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 19.36B |
| Agenus, Inc. | -221.22M |
| Altimmune, Inc. | 283.99M |
| Lineage Cell Therapeutics, Inc. | 53.88M |
| Amgen, Inc. | 9.19B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.673B |
| Total Liabilities (Quarterly) | 2.453B |
| Debt to Equity Ratio | 9.764 |
| Current Ratio | 2.762 |
| Net Debt Paydown Yield | -1.59% |